Bayer commences a second-stage trial using a novel anti-alpha2 antiplasmin agent in individuals affected by deep venous clots.

BuSpar® (buspirone hydrochloride) is an antianxiety agent that is not chemically or pharmacologically related to the benzodiazepines, barbiturates, or other sedative/anxiolytic drugs.

EU Regulatory Body Sanctions Pfizer's VELSIPITY® Use in Individuals with Moderate to Severe Ulcerative Colitis Cases.

The latest ASCO_GU 2024 update summarized new clinical findings on disitamab vedotin and toripalimab as an innovative neoadjuvant therapy for HER2+ advanced local MIBC patients.

Genentech announced that the US FDA has approved Xolair (omalizumab) for reducing allergic reactions.

Diclofenac sodium, a benzene-acetic acid derivative, is a nonsteroidal anti-inflammatory drug (NSAID) ,has analgesic, anti-inflammatory, and antipyretic properties.

US authorities greenlight a combined treatment of TAGRISSO® (osimertinib) and chemotherapy for individuals battling advanced lung cancer with EGFR mutations.

Datopotamab deruxtecan (Dato-DXd) is an ADC comprising a humanized anti-TROP2 IgG1 monoclonal antibody bonded to a potent topoisomerase I inhibitor through a stable, tumor-specific, cleavable tetrapeptide linker.

U.S. Authorities Approve Review for Deruxtecan-Datopotamab Treatment Submission for Earlier Managed Advanced Non-Squamous NSCLC Cases.

Tadalafil, sold as Cialis, is a PDE5 inhibitor, similar to sildenafil (Viagra) and vardenafil (Levitra).

Almirall gains rights to develop Novo Nordisk’s anti-IL-21 antibody for dermatologic applications as a pioneering treatment.

Early PSA response correlates with better outcomes in mHSPC patients receiving ADT and ARPIs.